Investigational drug · Phase 3
Nomlabofusp
Also called: CTI-1601
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Friedreich Ataxia, Friedreich's Ataxia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Nomlabofusp"
First trial start
2024
Jan 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nomlabofusp", any sponsor or status.
Conditions studied
As listed on its trial records.
- Friedreich Ataxia
- Friedreich's Ataxia
Approved drugs for the same conditions: Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nomlabofusp" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's AtaxiaPivotal-lookingRecruiting
Larimar Therapeutics, Inc.Industry
NCT07778836 · 150 participants (planned) · Start Aug 5, 2026 · Primary completion Jul 2029
Drug: Nomlabofusp; Placebo · For: Friedreich Ataxia; Friedreich's Ataxia
Sites: Tampa, Florida; Chicago, Illinois; Eatontown, New Jersey · 4 sites in all
Larimar Therapeutics, Inc.Industry
NCT06447025 · 85 participants (planned) · Start Jan 25, 2024 · Primary completion Jan 2027
Drug: CTI-1601 · For: Friedreich Ataxia
Sites: Los Angeles, California; San Francisco, California; Gainesville, Florida · 10 sites in all
Larimar Therapeutics, Inc.Industry
NCT06681766 · 18 participants · Start Dec 6, 2024 · Primary completion Apr 27, 2025
Drug: Nomlabofusp; Placebo · For: Friedreich Ataxia
Sites: Chevy Chase, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling.
De Toni F, Hamdani M, Patadia C, et al. · Clin Transl Sci 2026
- Pharmacokinetics and Pharmacodynamics of Nomlabofusp in Non-clinical Studies of Friedreich's Ataxia.
De Toni F, Ragaglia V, Schecter D, et al. · AAPS J 2025
- Nomlabofusp, a Fusion Protein of Human Frataxin and a Cell Penetrant Peptide, Delivers Mature and Functional Frataxin into Mitochondria.
Baile MG, Jones J, Sahr N, et al. · AAPS J 2025
- Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich's ataxia.
Clayton R, Galas T, Scherer N, et al. · Ann Clin Transl Neurol 2024
Also in development for Friedreich Ataxia
- VatiquinonePTC743Phase 33 trials
PTC Therapeutics · Friedreich's Ataxia, Friedreich Ataxia, Inherited Mitochondrial Disease
- DT-216P2Phase 21 trial
Design Therapeutics, Inc. · Friedreich Ataxia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.